Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Cyclobenzaprine Hcl
Generic Name
Cyclobenzaprine Hcl
Active Ingredient
CyclobenzaprineCategory
Other
Salt Form
Hydrochloride
Variants
7
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 7.5 mg/1 | TABLET, FILM COATED | ORAL | 80425-0078 |
| 5 mg/1 | TABLET, FILM COATED | ORAL | 80425-0155 |
| 5 mg/1 | TABLET, FILM COATED | ORAL |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Cyclobenzaprine Hcl, you must consult a qualified healthcare professional.
| 5 mg/1 | TABLET, FILM COATED | ORAL | 80425-0017 |
| 7.5 mg/1 | TABLET, FILM COATED | ORAL | 85509-1001 |
| 15 mg/1 | CAPSULE, EXTENDED RELEASE | ORAL | 80425-0292 |
| 10 mg/1 | TABLET, FILM COATED | ORAL | 80425-0018 |
Detailed information about Cyclobenzaprine Hcl
Cyclobenzaprine is a skeletal muscle relaxant used for the short-term relief of muscle spasms associated with acute, painful musculoskeletal conditions. It belongs to a class of medications that act centrally on the nervous system to reduce motor activity.
The dosage of cyclobenzaprine must be individualized based on the patient's response and the severity of the muscle spasms. According to the FDA-approved labeling:
Treatment duration should generally not exceed 2 to 3 weeks. If symptoms persist beyond this timeframe, your healthcare provider should re-evaluate the diagnosis.
Cyclobenzaprine is not recommended for use in pediatric patients under the age of 15. For adolescents aged 15 to 17, the adult dosing of 5 mg to 10 mg three times daily (for IR) or 15 mg once daily (for ER) may be considered by a specialist, though safety and efficacy data in this population are limited compared to adults.
Specific dosage adjustments for renal impairment are not typically provided in the standard labeling; however, because the drug is primarily excreted via the kidneys, healthcare providers should exercise caution. Monitoring for increased side effects is recommended in patients with significant kidney disease.
Cyclobenzaprine plasma levels are significantly increased in patients with hepatic (liver) insufficiency.
In patients 65 years and older, the clearance of cyclobenzaprine is reduced, and the half-life is prolonged. Elderly patients are also more susceptible to the sedative and anticholinergic effects (such as confusion and hallucinations). Healthcare providers usually start with the lowest possible dose (5 mg) and increase it only if absolutely necessary and well-tolerated.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not 'double up' or take two doses at once to make up for a missed one, as this increases the risk of CNS depression.
An overdose of cyclobenzaprine can be life-threatening. Symptoms of overdose may include severe drowsiness, rapid heartbeat (tachycardia), tremors, agitation, slurred speech, confusion, hallucinations, and in severe cases, cardiac arrest, chest pain, or seizures. If an overdose is suspected, contact emergency services (911) or a poison control center immediately. Treatment usually involves supportive care, gastric lavage if caught early, and cardiac monitoring.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. This medication is for short-term use only.
Cyclobenzaprine is known for its sedative properties. The most frequently reported side effects include:
Cyclobenzaprine is a potent medication that affects the central nervous system. It should only be used under the direct supervision of a healthcare professional. Patients should be aware that this drug can significantly impair mental and physical abilities. It is structurally related to tricyclic antidepressants, which means it carries many of the same risks and precautions associated with that class of drugs, even though it is used for muscle spasms.
No FDA black box warnings for Cyclobenzaprine. However, the absence of a black box warning does not imply the drug is without significant risk, particularly regarding cardiac health and drug interactions.
There are several conditions where the risks of cyclobenzaprine use clearly outweigh any potential benefit. In these cases, the drug must never be used:
Cyclobenzaprine was previously classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.
It is not known whether cyclobenzaprine is excreted in human milk. However, because it is chemically related to tricyclic antidepressants (some of which are excreted in breast milk), there is a potential for the drug to pass to the nursing infant. The primary concern is sedation or 'floppiness' in the baby. Healthcare providers usually recommend either discontinuing nursing or discontinuing the drug, taking into account the importance of the drug to the mother.
Cyclobenzaprine is a skeletal muscle relaxant that acts centrally. Its primary molecular target is the brainstem, specifically the locus coeruleus and the reticular formation. It does not act directly on the skeletal muscle or the motor endplate. By reducing the activity of somatic motor neurons (both alpha and gamma), it decreases the tonic muscle activity that characterizes a spasm. It is believed to increase the inhibitory effect of norepinephrine and potentially modulate serotonergic pathways, which leads to a reduction in the transmission of pain signals and a decrease in muscle 'firing' at rest.
Common questions about Cyclobenzaprine Hcl
Cyclobenzaprine is primarily used for the short-term treatment of muscle spasms that occur due to acute musculoskeletal conditions, such as back strains, neck injuries, or sports-related muscle tears. It is intended to be used alongside rest and physical therapy to help improve range of motion and reduce pain. Because it acts on the central nervous system to relax muscles, it is not effective for spasms caused by cerebral palsy or spinal cord injuries. Most healthcare providers prescribe it for a duration of only two to three weeks. Using it longer than this is generally not recommended because there is little evidence that it remains effective for chronic conditions. Always consult your doctor to see if your specific injury warrants the use of a muscle relaxant.
The most common side effects of cyclobenzaprine are related to its effects on the brain and its anticholinergic properties. Drowsiness is the most frequent complaint, affecting nearly one-third of all patients, which can make daily tasks like driving dangerous. Dry mouth is also very common and can be managed by sipping water or using sugarless candy. Many patients also report feeling dizzy or lightheaded, especially when moving from a sitting to a standing position. Other frequent issues include fatigue, constipation, and blurred vision. If these symptoms become severe or interfere with your daily life, you should contact your healthcare provider to discuss a possible dose adjustment. Most of these side effects are temporary and will resolve once the medication is stopped.
No, you should strictly avoid drinking alcohol while taking cyclobenzaprine. Both alcohol and cyclobenzaprine are central nervous system (CNS) depressants, meaning they slow down brain activity and physical reactions. When taken together, they can cause extreme drowsiness, severe dizziness, and a significantly increased risk of accidents or falls. In more serious cases, the combination can lead to respiratory depression, where breathing becomes dangerously slow or shallow. This interaction is particularly dangerous for elderly patients or those with underlying respiratory issues. To ensure your safety during treatment, it is best to abstain from all alcoholic beverages until the medication is completely out of your system. Talk to your doctor if you have concerns about alcohol use and this medication.
Cyclobenzaprine is generally only used during pregnancy if the potential benefit justifies the potential risk to the fetus. It was previously categorized as Pregnancy Category B, indicating that animal studies did not show harm, but there isn't enough high-quality data from human trials to guarantee absolute safety. Most doctors prefer to use non-pharmacological treatments like physical therapy, heat, or ice for muscle pain in pregnant women before considering this medication. If it is prescribed, it is usually for a very short duration and at the lowest effective dose. There is also a lack of information regarding whether the drug passes into breast milk, so nursing mothers should also exercise extreme caution. Always have a thorough discussion with your obstetrician before starting any new medication during pregnancy or while breastfeeding.
For most people, the effects of cyclobenzaprine begin within about 60 minutes of taking an immediate-release tablet. You will likely notice a decrease in muscle tension and a reduction in the sharp pain associated with spasms during this time. However, the peak effectiveness—when the drug reaches its highest concentration in your bloodstream—usually occurs about 3 to 4 hours after administration. For the extended-release version (Amrix), the onset may be similar, but the medication is designed to release slowly over a 24-hour period to provide consistent relief. It may take a day or two of regular dosing to achieve the full therapeutic benefit for significant muscle injuries. If you do not feel any improvement after several days of treatment, you should consult your healthcare provider for a re-evaluation of your symptoms.
If you have been taking cyclobenzaprine as directed for the standard short-term period of two to three weeks, you can usually stop taking it suddenly without experiencing major withdrawal symptoms. Unlike some other medications that affect the central nervous system, cyclobenzaprine is not typically associated with physical dependence when used correctly. However, if you have been using it off-label for a long period of time, stopping abruptly might cause mild symptoms like nausea, headache, or a general feeling of discomfort. In such cases, your doctor might suggest a gradual taper to avoid these issues. It is always best to finish the full course prescribed by your doctor unless you experience serious side effects. If you decide to stop early because your pain has resolved, simply inform your healthcare provider at your next visit.
If you miss a dose of cyclobenzaprine, you should take it as soon as you remember to maintain consistent levels of the medication in your body. However, if it is already close to the time for your next scheduled dose, it is safer to skip the missed dose entirely. You should never take two doses at the same time to 'catch up,' as this significantly increases the risk of excessive sedation, dizziness, and other dangerous side effects. Maintaining a regular schedule helps ensure the medication works effectively to keep muscle spasms under control. If you find yourself frequently forgetting doses, using a pill organizer or setting a phone alarm can be helpful. If you are unsure what to do after missing multiple doses, call your pharmacist or doctor for specific guidance.
Weight gain is not considered a common or direct side effect of cyclobenzaprine, especially when used for the recommended short-term duration of two to three weeks. Most clinical trials do not list weight changes as a significant concern for this medication. However, because the drug causes significant drowsiness and fatigue, some patients may become less physically active while taking it, which could theoretically lead to minor weight changes over time. Additionally, because it is structurally related to tricyclic antidepressants—a class of drugs known to sometimes cause weight gain—there is a theoretical risk with long-term, off-label use. If you notice rapid or unexplained weight gain while taking this medication, it is more likely related to another factor or a different health condition. Discuss any concerns about weight with your healthcare provider.
Cyclobenzaprine has several significant drug interactions that must be carefully managed by a healthcare provider. It should never be taken with MAO inhibitors, as this can cause a fatal reaction, and it should be used with extreme caution alongside other serotonergic drugs like SSRIs or SNRIs to avoid Serotonin Syndrome. It also interacts with other CNS depressants, such as opioids, benzodiazepines, and sleep medications, which can lead to dangerous levels of sedation and respiratory issues. Even over-the-counter medications like antihistamines can increase the risk of dry mouth and constipation. Because of these risks, it is vital to provide your doctor and pharmacist with a complete list of all medications, supplements, and herbal products you are currently taking. They can check for potential conflicts and ensure your treatment plan is safe.
Yes, cyclobenzaprine is widely available as a generic medication in its immediate-release tablet form. Generic versions are typically much more affordable than brand-name versions like Flexeril (which is now discontinued in the U.S.) and are considered bioequivalent, meaning they work the same way in the body. The extended-release version, formerly known only by the brand name Amrix, is also available in generic form (cyclobenzaprine ER). Most insurance plans cover the generic versions of this medication. When you receive your prescription, the tablets may look different depending on which manufacturer your pharmacy uses, but the active ingredient and its effectiveness remain the same. If you have questions about the specific generic brand you received, your pharmacist can provide detailed information about the manufacturer.
Other drugs with the same active ingredient (Cyclobenzaprine)
> Warning: Stop taking Cyclobenzaprine and call your doctor immediately if you experience any of these serious symptoms:
Cyclobenzaprine is not intended for long-term use (beyond 3 weeks). However, if used chronically off-label, patients may experience:
There are currently no FDA black box warnings for cyclobenzaprine. However, the FDA has issued strong warnings regarding its potential for interaction with MAO inhibitors and the risk of Serotonin Syndrome when combined with other serotonergic medications.
Report any unusual symptoms to your healthcare provider. Side effects are often dose-dependent and may resolve upon reducing the dose or discontinuing the medication.
For short-term use (under 3 weeks), routine laboratory monitoring is usually not required for healthy adults. However, for certain populations:
Cyclobenzaprine may impair the mental and/or physical abilities required for the performance of hazardous tasks, such as operating machinery or driving a motor vehicle. You should not drive or engage in activities requiring alertness until you know how this medication affects you. The sedative effect is most profound during the first few days of treatment.
Alcohol consumption must be avoided while taking cyclobenzaprine. Alcohol significantly increases the sedative and dizzying effects of the drug, which can lead to severe respiratory depression, profound lethargy, and an increased risk of falls or accidents.
While cyclobenzaprine is not considered an addictive substance in the traditional sense, abrupt discontinuation after long-term (off-label) use may occasionally result in withdrawal-like symptoms, such as nausea, headache, and malaise. For the standard 2-3 week course, tapering is generally not necessary, but you should always follow your doctor's specific instructions for stopping the medication.
> Important: Discuss all your medical conditions with your healthcare provider before starting Cyclobenzaprine, especially if you have a history of heart, liver, or eye problems.
Cyclobenzaprine does not typically interfere with standard laboratory tests (like glucose or cholesterol). However, it may cause false positives on certain urine drug screens for tricyclic antidepressants (TCAs) because of its structural similarity. If you are undergoing a drug screen, inform the laboratory that you are taking cyclobenzaprine.
For each major interaction, the management strategy usually involves avoiding the combination, adjusting the dose, or performing frequent clinical monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter cold medicines may contain ingredients that interact with cyclobenzaprine.
In these situations, a healthcare provider must perform a careful risk-benefit analysis before prescribing cyclobenzaprine:
Patients who have had a previous allergic reaction or hypersensitivity to Tricyclic Antidepressants (TCAs) (such as amitriptyline, nortriptyline, or imipramine) should not take cyclobenzaprine. Due to the nearly identical chemical structure, there is a very high likelihood of a cross-allergic reaction, which could manifest as anything from a mild rash to life-threatening anaphylaxis.
> Important: Your healthcare provider will evaluate your complete medical history, including heart health and eye health, before prescribing Cyclobenzaprine. Always disclose any history of heart 'skips' or 'palpitations'.
Safety and effectiveness of cyclobenzaprine in children under the age of 15 have not been established. Use in this population is generally avoided. In adolescents (15-17), it should be used at the lowest effective dose for the shortest duration possible, as the risk of CNS side effects may be higher.
The use of cyclobenzaprine in patients over 65 is generally discouraged. According to the Beers Criteria (a list of medications potentially inappropriate for older adults), cyclobenzaprine is listed as a drug to avoid due to its strong anticholinergic properties and the high risk of sedation and confusion.
While no specific dose adjustments are mandated for patients with kidney disease, the drug is primarily eliminated as metabolites in the urine. In patients with severe renal impairment, there is a theoretical risk of metabolite accumulation. Monitoring for increased side effects is the standard of care.
As the liver is the primary site of metabolism, hepatic impairment has a profound effect on cyclobenzaprine levels.
> Important: Special populations require individualized medical assessment. If you are pregnant or over 65, discuss alternative therapies like physical therapy or heat/ice application with your doctor.
| Parameter | Value |
|---|---|
| Bioavailability | 33% to 55% |
| Protein Binding | ~93% (primarily Albumin) |
| Half-life | 18 to 33 hours (Mean: 24h) |
| Tmax | 7 to 8 hours (IR); 7 to 8 hours (ER) |
| Metabolism | Hepatic (CYP3A4, 1A2, 2D6) |
| Excretion | Renal (primarily as conjugates) |
Cyclobenzaprine is classified as a centrally acting skeletal muscle relaxant. Within this broad category, it is often further sub-classified as a tricyclic-related agent. It is distinct from other relaxants like baclofen (a GABA-B agonist) or tizanidine (an alpha-2 adrenergic agonist) because of its unique brainstem-focused mechanism and TCA-like side effect profile.